Ready to upload
Adverse Occurrence type:
Most recent risk assessment for leukemia (Council of Europe, 2018): donors with active leukemia are considered to represent an unacceptable risk for tumor transmission. Data at this time do not allow for discrimination of individual types of leukemias. Donors with treated leukemia after a disease-free interval of 5 to 10 years are assumed to represent a high risk for tumor transmission.
Time to detection:
Alerting signals, symptoms, evidence of occurrence:
Recipient with sickle cell disease received peripheral blood stem cell transplant from HLA-identical brother. Day 100 BM post HSCT was normal with 95% chimerism but Phil chromosome in 9 of 31 metaphases; CBR ABL rearrangement in 14% of marrow cells.
Demonstration of imputability or root cause:
Philadelphia chromosome and BRC ABL rearrangement in both recipient and donor.
Suggest new keywords:
Allograft hematopoietic stem cell transplant
A new review is necessary - record unpublished (EP) Case reviewed (MN)
Expert comments for publication:
Recipient and donor both treated with remission. Authors believe this is the first report of CML transmission via peripheral blood stem cell transplantation (2003).